PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.44%
Revenue growth of 6.44% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
10.34%
Gross profit growth of 10.34% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
32.32%
EBIT growth of 32.32% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
35.65%
Operating income growth of 35.65% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
36.95%
Net income growth of 36.95% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
-31.52%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-31.52%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
100.00%
Share change of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if the modest difference matters long-term.
100.00%
Diluted share change of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight difference in equity issuance policy.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.06%
Negative 10Y revenue/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if the entire sector or just this company faces long-term decline.
-9.06%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-21.15%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-100.00%
Negative 3Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
15.25%
Net income/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff would push for cost or revenue enhancements to match peers.
15.25%
Net income/share CAGR of 15.25% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
6.59%
3Y net income/share CAGR of 6.59% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.61%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-100.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
-100.00%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
-99.47%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-2.66%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
1.83%
Asset growth of 1.83% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-47.19%
Negative BV/share change while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-76.30%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
52.94%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.